Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) Income towards Parent Company (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Income towards Parent Company data on record, last reported at -$35.6 million in Q3 2025.

  • For Q3 2025, Income towards Parent Company fell 17.47% year-over-year to -$35.6 million; the TTM value through Sep 2025 reached -$97.8 million, down 25.68%, while the annual FY2024 figure was -$68.4 million, 43.88% down from the prior year.
  • Income towards Parent Company reached -$35.6 million in Q3 2025 per ABEO's latest filing, down from -$23.7 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at -$8.3 million in Q2 2022 and bottomed at -$46.7 million in Q4 2021.
  • Average Income towards Parent Company over 5 years is -$18.7 million, with a median of -$15.5 million recorded in 2021.
  • Peak YoY movement for Income towards Parent Company: surged 71.9% in 2022, then crashed 164.61% in 2024.
  • A 5-year view of Income towards Parent Company shows it stood at -$46.7 million in 2021, then soared by 71.9% to -$13.1 million in 2022, then decreased by 1.56% to -$13.3 million in 2023, then crashed by 33.31% to -$17.8 million in 2024, then tumbled by 100.28% to -$35.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Income towards Parent Company were -$35.6 million in Q3 2025, -$23.7 million in Q2 2025, and -$20.7 million in Q1 2025.